iShares US Pharma

Eli Lilly to participate in the BioCentury-BayHelix East-West BioPharma Summit in Seoul, Korea

Eli Lilly to Participate in BIOCHINA Event in Suzhou, China

Eli Lilly to Participate in BIO-Europe Spring in Lisbon, Portugal

FDA decision on Lilly's oral weight-loss drug Orforglipron expected by April 10, 2026

Eli Lilly and Company will participate in the BIO-Korea 2026 conference in Seoul, Korea.

Modern Wealth Management Increases Holdings in Merck

New Study Suggests GLP-1 Drugs May Increase Risk of Bone Injuries

MILESTONE ASSET MANAGEMENT Increases Stake in Eli Lilly and Co.

Eli Lilly's competitor Novo Nordisk will reportedly partner with Hims & Hers to sell weight-loss drugs, potentially intensifying market competition

Eli Lilly and Company to Pay Quarterly Dividend

Eli Lilly's obesity drugs are expected to be available at a discount to U.S. Medicare beneficiaries

Forbes reports Eli Lilly used AI to increase production of its popular GLP-1 drugs.

Analyst discusses Eli Lilly's dominance in the GLP-1 drug market and its outlook for the next decade.

Wall Street Zen Upgrades Eli Lilly and Company to 'Strong-Buy'

TEACHER RETIREMENT SYSTEM OF TEXAS Sells Shares of Eli Lilly and Co (LLY)

US FDA Approves BMS's Sotyktu for Active Psoriatic Arthritis

Several investment management firms adjust their holdings in Eli Lilly and Company.

Eli Lilly Faces Actos RICO Class Action Lawsuit

Deutsche Bank Maintains Buy Rating on Eli Lilly and Company

Eli Lilly CEO's Total Compensation for 2025 is $36.7 Million

Peraso

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

Decent

Edesa Biotech

Cre8 Enterprise - CL

AN2 Therapeutics

Day One Biopharmaceuticals

Epsium Enterprise

Silynxcom

Aptera Motors - B

Pinned News

置顶新闻

Modern Wealth Management LLC Has $2.83 Million Position in Merck & Co., Inc. $MRK

ARKG

Modern Wealth Management LLC increased its stake in Merck & Co., Inc. by 61.2% in Q3, owning 33,675 shares valued at $2.83 million. Other institutional investors also raised their holdings. Merck's stock opened at $115.85, with a market cap of $286.43 billion. The company reported Q4 earnings of $2.04 per share, exceeding estimates, and announced a quarterly dividend of $0.85. Insiders have sold shares recently, indicating changes in ownership.

Market Beat

Ark Genomic Revolution ETF

Merck

SPDR S&P Biotech

iShares Global Healthcare

BNTX

SBIO

IBBQ

Earnings This Week – March 9-13, 2026

Tip Ranks

BioNTech SE

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Earnings This Week – March 9-13, 2026

Kessler Topaz Meltzer & Check, LLP has announced a securities fraud class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for investors who purchased shares between August 3, 2023, and December 26, 2025. The lawsuit alleges material misstatements regarding the company's drug, setrusumab, and investors have until April 6, 2026, to seek lead plaintiff status. Following the announcement of disappointing Phase III study results, Ultragenyx's stock price dropped over 42%. Affected investors are encouraged to contact KTMC for recovery options at no cost.

prnewswire

VG Health

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Ultragenyx Pharma

Health Care Select Sector SPDR

12:00 ETRARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm

In March 2026, the FDA granted Priority Review for Protagonist Therapeutics' rusfertide, a hepcidin mimetic peptide for polycythemia vera, with a PDUFA date in Q3. This development could reshape Protagonist's investment narrative, as the company faces ongoing losses and a significant reliance on this regulatory decision. While shares have risen, they may still be undervalued, with fair value estimates ranging from US$108 to US$354. Investors must consider the risks of regulatory setbacks and the company's financial health before making decisions.

Simplywall

Protagonist Therap

Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)?

Modern Wealth Management LLC increased its stake in Johnson & Johnson (NYSE: JNJ) by 10.8% in Q3, now holding 44,105 shares valued at $8.18 million. Other institutional investors, including Vanguard and Geode Capital, also raised their stakes. Johnson & Johnson's stock opened at $240.57, with a market cap of $579.75 billion and a PE ratio of 21.77. The company declared a quarterly dividend of $1.30 per share, with a yield of 2.2%. Analysts have set target prices ranging from $220 to $255, with a consensus rating of "Moderate Buy."

Johnson & Johnson

SPDR S&P Health Equip

iShares US Medical Devices

Modern Wealth Management LLC Increases Stock Position in Johnson & Johnson $JNJ

Bank of America Securities has reaffirmed a Sell rating on TG Therapeutics, Inc. (NASDAQ:TGTX) following its earnings report. Analyst Alec Stranahan set a price target of $15, which is the lowest among Wall Street estimates. Despite being listed as one of the 13 Most Profitable Growth Stocks to Buy Right Now, the bearish outlook reflects concerns about the company's performance.

TG Therap

Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings

LABD

Wave Life Sciences Ltd. reported a significant decline in Q4 2025 sales to $17.24 million, with a net loss of $53.18 million, compared to a profit last year. Despite these losses, the company is pursuing an accelerated approval pathway for its drug WVE-006 for alpha-1 antitrypsin deficiency, which may enhance its investment narrative. Analysts express concerns over liquidity and potential revenue declines, while the company projects $177.5 million in revenue by 2028, suggesting a fair value of $33.50, indicating a 155% upside from current prices.

Direxion S&P Biotech Bear 3X

SPDR Pharmac

Wave Life Sciences

Bioshares Biotech Clinical Trials Fd

Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed

VRTX

Codex Capital Asset Management L.L.C. reduced its stake in Vertex Pharmaceuticals by 38.3% in Q3, now holding 7,250 shares valued at $2.84 million. Other institutional investors, including Vanguard and Geode Capital, have also adjusted their positions. Vertex's stock opened at $456.69, with a market cap of $116.01 billion. The company reported a quarterly EPS of $5.03, slightly missing estimates, with revenue up 9.5% year-over-year. Insider transactions included sales by executives, and analysts have varied ratings on the stock, with Canaccord Genuity raising its target price to $441.00.

Vertex Pharma

Codex Capital Asset Management L.L.C. Has $2.84 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Grantham Mayo Van Otterloo & Co. LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 4.6% in Q3, now holding 8,176,484 shares valued at approximately $1.1 billion. The stock represents 3.1% of their portfolio. Other institutional investors also adjusted their holdings. Abbott's stock recently opened at $109.74, down 1.2%, with a market cap of $190.69 billion. The company announced a quarterly dividend of $0.63 per share, with a yield of 2.3%. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy."

Abbott Laboratories

Abbott Laboratories $ABT Position Raised by Grantham Mayo Van Otterloo & Co. LLC

ABBV

Gabelli Funds LLC has reduced its stake in AbbVie Inc. (NYSE:ABBV) by 6.2%, now holding 100,963 shares valued at $23.38 million. Other institutional investors have also adjusted their positions in AbbVie. Analysts have mixed ratings on the stock, with a consensus price target of $253.15. AbbVie recently reported earnings of $2.71 per share, exceeding estimates, and declared a quarterly dividend of $1.73 per share, yielding 3.0%. The stock is currently trading at $230.41, down 0.8%.

Abbvie

Gabelli Funds LLC Decreases Stake in AbbVie Inc. $ABBV

Gamco Investors INC. ET AL reduced its stake in Pfizer Inc. by 16.1% in Q3, selling 107,937 shares, leaving them with 563,304 shares valued at $14.35 million. Other institutional investors, including Vanguard and Geode Capital, also adjusted their holdings. Positive developments for Pfizer include the approval of its GLP-1 weight-management drug in China and upgrades from analysts, while challenges such as declining COVID revenues and competition remain.

- Gamco Investors INC. ET AL decreased its stake in Pfizer Inc. by 16.1%, now holding 563,304 shares worth approximately $14.35 million.  
- Institutional investors, including Vanguard Group Inc. and Geode Capital Management LLC, have increased their positions, indicating significant interest in Pfizer shares, which are currently dominated by hedge funds.  
- Recent developments include positive market responses to Pfizer’s GLP-1 weight management drug approval in China, while there are concerns about potential declines in COVID-related revenues and other market risks.

Pfizer

Direxion Daily Biotech Top 5 Bull 2X ETF

Gamco Investors INC. ET AL Sells 107,937 Shares of Pfizer Inc. $PFE

B. Metzler seel. Sohn & Co. AG has reduced its stake in Vertex Pharmaceuticals (NASDAQ: VRTX) by 1.3% in Q3, now holding 315,422 shares valued at approximately $123.5 million. This makes Vertex 1.1% of their portfolio. Other institutional investors have also adjusted their holdings, with Brighton Jones LLC increasing theirs by 15%. Analysts maintain a positive outlook on Vertex, with a consensus price target of $542. Recent insider sales have occurred, with executives selling shares valued at over $42 million in the last quarter.

B. Metzler seel. Sohn & Co. AG Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX

CPIX

Cipla USA, Inc, a subsidiary of Cipla, is recalling over 400 cartons of Nilotinib Capsules (150 mg and 200 mg) due to manufacturing issues, as reported by the USFDA. The Class III voluntary recall, initiated on February 18, indicates that exposure to the product is not likely to cause adverse health consequences. Nilotinib is used to block cancer cell multiplication. Indian pharmaceutical companies play a significant role in supplying medications to the US market, with a substantial share of prescriptions filled by them in 2022.

Business Standard

Cumberland Pharma

Citius Pharma

Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA

ARDX

Ardelyx (ARDX) is currently priced at approximately $6.19, reflecting a 5.5% decline over the past week and a 16.1% decline over the last month. Despite a 16.8% return over the past year, the stock is considered undervalued by 89.5% based on a Discounted Cash Flow (DCF) analysis, which estimates an intrinsic value of $58.79 per share. Additionally, Ardelyx's Price-to-Sales (P/S) ratio of 3.73x is below industry averages, indicating further undervaluation. Investors are encouraged to consider their own narratives regarding the company's future performance.

Ardelyx

Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility

STOK

Biogen and Stoke Therapeutics reported positive clinical results for zorevunersen in Dravet syndrome, indicating potential as a disease-modifying therapy. Biogen also shared new data on SPINRAZA for spinal muscular atrophy (SMA) and advanced salanersen into Phase 3 trials. These developments enhance Biogen's position in neurology and rare diseases, with a focus on high unmet needs. Investors should monitor upcoming regulatory milestones and the company's ability to convert late-stage assets into successful products amidst competition. Analysts highlight both risks and potential rewards related to Biogen's evolving pipeline.

Stoke Therapeutics

Biogen

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

Codexis CEO Alison Moore highlighted the company's focus on RNA medicines manufacturing at the TD Cowen Health Care Conference, targeting significant growth by 2026 through its ECO Synthesis platform. The RNA medicines market is expanding, with Codexis addressing challenges in oligonucleotide production. The legacy biocatalysis business faces competition but supports Phase III assets. A supply assurance agreement with Merck enhances supply chain security, while Codexis engages with CDMOs for technology transfer and commercial licensing. The total addressable market for RNA medicines is estimated at $2 billion by 2030.

Codexi

Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Eli Lilly

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

iShares US Pharma(IHE.US)

Modern Wealth Management LLC Has $2.83 Million Position in Merck & Co., Inc. $MRK

Earnings This Week – March 9-13, 2026

12:00 ETRARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm

Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)?

Modern Wealth Management LLC Increases Stock Position in Johnson & Johnson $JNJ